IntroductionThe identification of immune surrogate markers plays an important role in vaccine research toward the prevention of infectious diseases (Plotkin, ). Since efficacy trials measuring clinical endpoints of interest are costly and operationally challenging to conduct, early vaccine development relies heavily on phase I–II immunogenicity studies in which candidate vaccines are screened and selected based on the magnitude, breadth, and quality of the immune responses they elicit. The identification of immune response markers (i.e., surrogate endpoints) that can reliably predict a vaccine's protective effect, is thus essential for reducing the cost and time of vaccine development.This article focuses on evaluating immune surrogates under the principal surrogate (PS) framework (Frangakis and Rubin, ), using data from a randomized trial. As discussed in Gilbert et al. (), this framework is particularly advantageous for surrogates evaluation in vaccine studies compared to alternative frameworks (Joffe and Greene, ) such as those based on assessing the Prentice criteria (Freedman et al., ), direct and indirect effects of treatment (Robins and Greenland, ), and a meta‐analytical approach that combines multiple trials (Daniels and Hughes, ). Under the PS framework, we can assess an immune response's surrogate value through the estimation of a vaccine efficacy (VE) curve, which
Biometrics – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud